Should a patient with a left atrial myxoma who has experienced a stroke receive anticoagulation therapy?

Anticoagulation in Left Atrial Myxoma with Stroke

Do not initiate therapeutic anticoagulation for stroke in the setting of left atrial myxoma—anticoagulation does not prevent tumor embolization, increases hemorrhagic transformation risk, and must not replace urgent surgical resection. 1

Rationale Against Therapeutic Anticoagulation

Therapeutic anticoagulation (unfractionated heparin or LMWH) should not be started for acute stroke caused by myxoma because it raises hemorrhagic risk without preventing tumor embolization. 1 The mechanism of stroke in myxoma is embolization of tumor fragments or thrombus adherent to the tumor surface—anticoagulation cannot address the underlying source and provides no benefit. 1, 2

Key Evidence Points:

• Anticoagulation or antiplatelet therapy alone is insufficient to prevent embolic complications and must not replace definitive surgical resection. 1, 2, 3

• The overall embolism rate with cardiac myxomas is 25%, with embolic stroke being the presenting symptom in up to 50% of cases. 1, 2

• Myxomas with villous or papillary surface architecture have markedly higher embolic potential, making mechanical prevention through surgery even more critical. 2

Limited Role for Antiplatelet Therapy

Aspirin 160–325 mg may be given 24–48 hours after stroke onset (once hemorrhage is excluded) unless cardiac surgery is planned within that window. 1 This represents minimal antiplatelet coverage rather than therapeutic anticoagulation.

• If intravenous alteplase has been administered, aspirin should be delayed more than 24 hours post-thrombolysis to minimize bleeding risk. 1

VTE Prophylaxis Exception

Subcutaneous low-molecular-weight heparin (e.g., enoxaparin 40 mg daily) or unfractionated heparin 5,000 IU twice daily is recommended for immobilized stroke patients specifically for VTE prophylaxis. 1 This prophylactic-dose anticoagulation serves a different purpose than therapeutic anticoagulation for stroke prevention and is appropriate.

• Intermittent pneumatic compression should be added for additional VTE risk reduction. 1

Definitive Management: Urgent Surgery

The American College of Cardiology gives a Class I recommendation for urgent surgical resection of symptomatic left atrial myxoma because the tumor has a 25% overall embolism rate and stroke is the presenting symptom in up to 50% of cases. 1

Surgical Timing Algorithm:

• Urgent cardiac surgery (within 2–24 hours of stroke onset) is advised when:

  • The infarct is small-to-moderate 1
  • The patient is neurologically stable 1
  • No hemorrhagic transformation is evident on initial or 24-hour follow-up imaging 1

• Delay surgery 7–14 days if:

  • Hemorrhagic transformation develops 1
  • The infarct involves more than 1/3 of the middle cerebral artery territory 1
  • The patient shows neurological instability 1

• Complete tumor excision with an adequate atrial-septal margin (including the fossa ovalis attachment) is required to keep recurrence risk low (1–5% in sporadic cases). 1

Critical Pitfalls to Avoid

• Do not rely on anticoagulation or antiplatelet agents as definitive therapy; they do not prevent tumor embolization nor relieve mechanical obstruction. 1, 2

• Do not postpone cardiac surgery for weeks or months in stable patients; the risk of recurrent embolization outweighs concerns about operating in the sub-acute stroke period. 1

• One case report 4 mentions anticoagulant therapy being administered, but this contradicts current guideline recommendations and represents outdated practice. 1

• Careful monitoring is essential because hemorrhagic transformation may alter the timing of surgery for tumor resection. 5 One case delayed surgery 4 weeks due to concerns about anticoagulation required for cardiopulmonary bypass 6, but current guidelines favor much earlier intervention when feasible. 1